A patient’s transition from “living” to “dying” is not socially marked in the same way death is marked, and this is both clinically and ethically relevant.
AMA J Ethics. 2020;22(12):E1062-1066. doi:
10.1001/amajethics.2020.1062.
Adhering too strictly to biomedical thinking about diagnosis can prevent clinicians from empathically engaging with patients and helping them navigate their illness experiences.
AMA J Ethics. 2021;23(7):E537-541. doi:
10.1001/amajethics.2021.537.
Fragmentation in US health care delivery streams and shortcomings in formal quality measures mean that transparency could be more useful to policymakers and regulators than patients.
AMA J Ethics. 2022;24(11):E1075-1082. doi:
10.1001/amajethics.2022.1075.
Sarosh Nagar, Leah Z. Rand, PhD, and Aaron S. Kesselheim, MD, JD, MPH
This article analyzes differences in prescription drug pricing transparency practices among 3 Organisation of Economic Co-operation and Development member nations.
AMA J Ethics. 2022;24(11):E1083-1090. doi:
10.1001/amajethics.2022.1083.